RAPT
RAPT Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RAPT
Rapt Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for cancer and inflammatory diseases
561 Eccles Avenue, South San Francisco, California 94080
--
RAPT Therapeutics, Inc., was incorporated in March 2015 under the laws of the State of Delaware. The Company is a clinical-stage, immunology-based biopharmaceutical company dedicated to the discovery, development and commercialization of oral small molecule therapies for patients who are not fully satisfied in oncology and inflammatory diseases. Using its proprietary drug discovery and development engine, the company develops highly selective small molecules designed to modulate key immune responses in these diseases.
Company Financials
EPS
RAPT has released its 2025 Q3 earnings. EPS was reported at -0.65, versus the expected -0.85, beating expectations. The chart below visualizes how RAPT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
